Journal of Cerebral Blood Flow & Metabolism · 2008 · 84 citations · 29 references
Life SciencesImmunologyPharmacologyInflammationInnate ImmunityNeuroimmunologyAcute Ischemic StrokeCerebrovascular PhysiologyLeukocyte AdhesionLeukocyte RecruitmentNeuroinflammationNeuroprotectionAnaphylatoxin-mediated InflammationGranulocyte ResponsesInflammatory Cell InjuryIntercellular Adhesion Molecule 1Leukocyte FunctionNeuroinflammation In StrokeRodent Cerebral IschemiaTissue Infiltration By Inflammatory Cells
The complement anaphylatoxin C3a contributes to injury after cerebral ischemia in mice. This study assesses the effect of C3a receptor antagonist (C3aRA) on leukocyte infiltration into the ischemic zone. Transient or permanent middle cerebral artery occlusion (MCAO) was induced in wild-type C57Bl/6 mice. Intraperitoneal C3aRA or vehicle was administered 45 mins before or 1 h after occlusion. Twenty-four hours after occlusion, we harvested brain tissue and purified inflammatory cells using flow cytometry. Soluble intercellular adhesion molecule (ICAM)-1 protein levels were assessed using enzyme-linked immunosorbent assays, and ICAM-1 and C3a receptor (C3aR) expression was confirmed via immunohistochemistry. In the transient MCAO model, animals receiving C3aRA showed smaller strokes, less upregulation of C3aR-positive granulocytes, and less ICAM-1 protein on endothelial cells than vehicle-treated animals; no significant differences in other inflammatory cell populations were observed. C3a receptor antagonist-treated and vehicle-treated animals showed no differences in stroke volume or inflammatory cell populations after permanent MCAO. These data suggest that blocking the binding of C3a to C3aR modulates tissue injury in reperfused stroke by inhibiting the recruitment of neutrophils to the ischemic zone. It further establishes antagonism of the C3a anaphylatoxin as a promising strategy for ameliorating injury after ischemia/reperfusion.
29
Complement-dependent Clearance of Apoptotic Cells by Human Macrophages
Dror Mevorach, John Mascarenhas, Debra Gershov et al. · The Journal of Experimental Medicine · 1998 · 692 citations · Full text
E. Sander Connolly, Christopher J. Winfree, Timothy A. Springer et al. · Journal of Clinical Investigation · 1996 · 528 citations · Full text
Life Sciences, Immunology, Neurology +17
Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN)
Michael Krams, Kennedy R. Lees, Werner Hacke et al. · Stroke · 2003 · 429 citations
Complement: a novel factor in basal and ischemia‐induced neurogenesis
Yalda Rahpeymai, Max Albert Hietala, Ulrika Wilhelmsson et al. · The EMBO Journal · 2006 · 277 citations · Full text
Medicine, Neurobiology, Neuroscience +14